605199 Hainan Huluwa Pharmaceutical Group
- 9.32
- -0.14-1.48%
About Hainan Huluwa Pharmaceutical Group Company
The company takes “Healthy China Baby” as its corporate mission, protects the healthy growth of Chinese children, and is committed to building a national brand of Chinese children's medicine. The company is a group enterprise headquartered in Haikou. It was restructured in 2008 and listed on the main board of the Shanghai Stock Exchange in July 2020. It is the first company listed on the main board in Hainan since the announcement of the overall plan for the construction of the Hainan Free Trade Port. It focuses on drug research and development, production, and sales. The product categories cover specialty traditional Chinese medicines, chemical drugs, etc. We have developed a product plan that mainly focuses on children's medicines and combines them with adult medicine, and is laid out around children's respiratory system, digestive system, anti-infective drugs, and other drugs. Main products: Pediatric pulmonary fever, cough and asthma granules, enteritis tablets, compound fresh dendrobium granules, cough tablets, pediatric aminophen xanthamine granules, compound cold tablets, compound lysine granules, etc. Corporate honors: In June 2018, Huluwa Pharmaceutical won the title of “VIP Strategic Cooperation Enterprise” by the China Pharmaceutical Business Association; in March 2018, Huluwa Pharmaceutical won the “Brand Leadership Award” at the China Brand Pharmacy Business Summit; in December 2017, Huluwa Pharmaceutical won the honorary title of “Big Country Brand”. It has won honors such as “Leading Force China Pharmaceutical High Quality Development Achievement Enterprise”, China's National Pharmaceutical Excellent Brand Enterprise, China Pharmaceutical Industry's Most Popular Brand Enterprise, Retail Pharmacy's Most Popular Brand Enterprise, etc., and won many industry honors such as “2022 China Pharmacy Chain Most Cooperative Value Brand Award” and China Pharmaceutical's “2022 Chinese Pharmaceutical Brand List Award”. It has won honors such as Star Club's “Most Popular Star Item in Retail Pharmacies” and Sipuhui's “2023 Brand Top List”.
Company Profile
Company Executives
- Name
- Position
- Salary
- jingping liu
- Chairman, Directors, General Manager, Chairman of the Strategy and ESG Committee, Nomination Committee Members
- 1.41M
- hui yu
- Directors, Deputy General Manager, Chief Financial Officer, Member of the Remuneration and Assessment Committee
- 1.12M
- junling li
- Directors, Deputy General Manager, Audit Committee Member
- 1.14M
- qibo tang
- Directors, Member of the Strategy and ESG Committee
- 635.20K
- qiuyun liu
- Independent Directors, Chairman of the Audit Committee, Member of the Remuneration and Assessment Committee
- 100.00K
- shixian wang
- Independent Directors, Audit Committee Member, Chairman of the Remuneration and Assessment Committee, Nomination Committee Members
- 100.00K
- guihua wang
- Independent Directors, Member of the Strategy and ESG Committee, Chairman of the Nomination Committee
- 100.00K
- qingtao wang
- Board Secretary
- 517.80K
- haiyan wang
- Securities Affairs Representative
- --
- peng xu
- Chairman of the Supervisory Board, Auditors
- 259.10K
- ping liu
- Auditors
- 314.30K
- peihu li
- Deputy General Manager
- 477.00K
- tianbao wei
- Deputy General Manager
- 435.70K
- baokun wan
- Employee Supervisors
- 304.10K
Analysis
Price Target
No Data
